Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia

Journal of Urology

Volumn 166, Issue 4, 2001, Pages 1358-1363

  Schulman, Claude C ^b   Lock, Tycho M T W ^b   Buzelin, Jean Marie ^b   Boeminghaus, Frank ^b   Stephenson, Tim P ^b   Talja, Martti ^b  

^a ERASME HOSPITAL   (Belgium)

^b NONE

Author keywords

Adrenergic; Alpha 1; Prostate; Prostatic hyperplasia; Receptors; Urination disorders

Indexed keywords

TAMSULOSIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; TREATMENT OUTCOME; URETHRA DISEASE;

EID: 0034837471     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)65769-2     Document Type: Article

References (20)

1. Recommendations of the International Scientific Committee: The evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction
2. Doxazosin for benign prostatic hyperplasia: Long-term efficacy and safety in hypertensive and normotensive patients
3. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia
4. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial
5. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia
6. Tamsulosin: 3-Year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: Analysis of a European, multinational, multicenter, open-label study
7. Tamsulosin, a selective alpha 1C-adrenoceptor antagonist: A randomized, controlled trial in patients with benign prostatic obstruction (symptomatic BPH)
8. 1A-adrenoceptor antagonists. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH)
9. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia)
10. A second phase III multicenter placebo-controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia
11. Tamsulosin 0.4 mg daily: Effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
12. Clinical comparison of selective and nonselective α1A-adrenoceptor antagonists in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses
13. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: Studies on tamsulosin and terazosin in Chinese patients
14. Natural history of prostatism: Risk factors for acute urinary retention
15. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia
16. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists
17. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
18. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
19. Orthostatic effects of alfuzosin twice daily vs. tamsulosin once daily in the morning
20. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing